Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Inclusion Criteria: * Computed tomography (CT) evidence of proximal PE (filling defect in at least one main or segmental pulmonary artery) * PE symptom duration less than or equal to (\<=)14 days * Informed consent can be obtained from participant or Legally Authorized Representative (LAR) * Massive PE (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) or * Submassive PE (RV diameter-to-LV diameter greater than or equal to \[\>=\] 0.9 on contrast-enhanced chest CT) Exclusion Criteria: * Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year * Recent (within one month) or active bleeding from a major organ * Hematocrit less than (\<) 30 percent (%) * Platelets \< 100 thousand/microliter (mcL) * International Normalized Ratio (INR) greater than (\>) 3 * Activated partial thromboplastin time (aPTT) \>50 seconds on no anticoagulants * Major surgery within seven days of screening for study enrollment * Serum creatinine \>2 milligrams/deciliter (mg/dL) * Clinician deems high-risk for catastrophic bleeding * History of heparin-induced thrombocytopenia (HIT) * Pregnancy * Catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment * Systolic blood pressure less than 80 mm Hg despite vasopressor or inotropic support * Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR) * Evidence of irreversible neurological compromise * Life expectancy \<30 days * Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study * Previous enrollment in the SEATTLE study